8-K: Arvinas Announces Positive Preclinical Data for PROTAC BCL6 Degrader ARV-393 in Combination Therapies for B-Cell Lymphoma

Arvinas' ARV-393, a PROTAC BCL6 degrader, shows synergistic antitumor activity in preclinical studies when combined with standard-of-care and investigational therapies for B-cell lymphoma.

Summary

• Arvinas presented preclinical data on ARV-393, an investigational PROTAC BCL6 degrader, at the 2025 AACR annual meeting.
• The data demonstrated synergistic antitumor activity, including complete regressions, when ARV-393 was combined with standard-of-care chemotherapy, biologics, and investigational oral small molecule inhibitors in high-grade B-cell lymphoma (HGBCL) and aggressive diffuse large B-cell lymphoma (DLBCL) models.
• ARV-393, combined with R-CHOP chemotherapy, resulted in significantly greater tumor growth inhibition and complete tumor regressions in all mice treated with the combination.
• When combined with biologics targeting CD20, CD19, or CD79b, ARV-393 led to tumor regressions and stronger tumor growth inhibition compared to each agent alone.
• ARV-393 increased CD20 expression in preclinical models, supporting its combination with CD20-targeted agents.
• Combining ARV-393 with small molecule inhibitors targeting BTK, BCL2, or EZH2 resulted in superior tumor growth inhibition and tumor regressions in all mice treated with the combinations.
• A Phase 1 study of ARV-393 is currently enrolling patients with relapsed/refractory non-Hodgkin lymphoma, including DLBCL (NCT06393738).

Sentiment

Score: 8

Explanation: The document presents highly positive preclinical data, suggesting significant potential for ARV-393 in lymphoma treatment. The management's comments further reinforce this positive outlook.

Positives

• ARV-393 shows promising preclinical results in combination with various lymphoma treatments.
• The observed complete tumor regressions in preclinical models are highly encouraging.
• ARV-393 increased CD20 expression, potentially enhancing the efficacy of CD20-targeted therapies.
• The ongoing Phase 1 clinical trial indicates progress towards potential therapeutic application.

Risks

• The data presented are preclinical, and results may not translate to human clinical trials.
• The success of the Phase 1 clinical trial is not guaranteed.
• The development of ARV-393 is subject to various risks and uncertainties, including regulatory hurdles and competition.

Future Outlook

Arvinas plans to continue evaluating ARV-393 combinations in non-Hodgkin lymphoma and is working to bring forward new therapeutic options for lymphoma patients. A Phase 1 study of ARV-393 is enrolling patients with relapsed/refractory non-Hodgkin lymphoma, including DLBCL.

Management Comments

• 'We are encouraged by the strength of these preclinical combination data, which demonstrate complete tumor regressions in aggressive lymphoma models,' said Noah Berkowitz, M.D., Ph.D., Chief Medical Officer at Arvinas.
• 'We believe these preclinical data demonstrate potential for broad combinability of ARV-393 and provide a compelling rationale for considering combination strategies as we work to bring forward new therapeutic options for lymphoma patients.'

Industry Context

The development of ARV-393 as a PROTAC BCL6 degrader aligns with the industry's focus on targeted protein degradation as a novel therapeutic approach. Combination therapies are a cornerstone of lymphoma treatment, and ARV-393's potential to enhance the efficacy of existing and investigational treatments could position it as a valuable addition to the lymphoma treatment landscape.

Comparison to Industry Standards

• Several companies are developing therapies for B-cell lymphomas, including those targeting BCL6.
• PROTAC technology is being explored by companies like C4 Therapeutics and Kymera Therapeutics, but ARV-393's specific focus on BCL6 degradation in lymphoma is a differentiating factor.
• The reported complete tumor regressions in preclinical models are competitive with other novel lymphoma therapies in early development.

Stakeholder Impact

• Positive preclinical data could benefit shareholders through increased stock value.
• Successful development of ARV-393 could provide a new treatment option for lymphoma patients.
• Employees may benefit from the company's progress and potential growth.

Next Steps

• Continue enrollment in the Phase 1 clinical trial of ARV-393 (NCT06393738).
• Further evaluate ARV-393 combinations in non-Hodgkin lymphoma.
• Advance ARV-393 towards potential therapeutic application for lymphoma patients.

Key Dates

Keywords

ARV-393, BCL6 Degrader, PROTAC, Lymphoma, B-Cell Lymphoma, Non-Hodgkin Lymphoma, Preclinical Data, Combination Therapy, Arvinas, AACR